MicroRNAs: Regulators of Cellular Fate

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: 31 July 2025 | Viewed by 107

Special Issue Editor

Special Issue Information

Dear Colleagues,

MicroRNAs (miRNAs) are among the most abundant non-coding RNAs and play a significant role in various biological processes, including disease progression. MicroRNAs are remarkably conserved across species, which reflects their essential biological functions. The evolutionary conservation of miRNAs strengthens their use as cross-species models for studying disease mechanisms and drug discovery. Understanding the gene regulation by miRNAs at the post-transcriptional level is therefore crucial. Indeed, the 2024 Nobel Prize in Physiology or Medicine was awarded to researchers for their discovery of miRNAs, thus highlighting the continuing importance of studying miRNAs.

In recent years, the identification of miRNA biomarkers for disease diagnosis has emerged as a prominent area of study. Beyond biomarker exploration, miRNA-based therapeutics—such as targeted treatments and drug discovery involving miRNAs—present exciting yet challenging opportunities for researchers. Utilizing miRNA biomarkers for diagnosis and miRNA-targeted treatments holds great promise for advancing personalized medicine. We therefore invite you to submit reviews and original research papers to this Special Issue on miRNA-related studies, including miRNA functionality through biological and computational approaches, the application of miRNA biomarkers, miRNA evolution, and other related topics.

Prof. Dr. Hsiuying Wang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • microRNA targets
  • microRNA conservation
  • microRNA pathway
  • microRNA mimics
  • microRNA antagonist
  • disease biomarker

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop